Ignite Creation Date:
2025-12-25 @ 1:09 AM
Ignite Modification Date:
2026-01-04 @ 8:03 PM
Study NCT ID:
NCT01110993
Status:
COMPLETED
Last Update Posted:
2014-02-03
First Post:
2010-04-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EMR 701068-516
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None